organization · Reporting owner
Ogden CAP Associates, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COGNITION THERAPEUTICS INCCGTX · Entity 6792 | 10% owner | October 13, 2021 | October 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COGNITION THERAPEUTICS INC
Report date October 13, 2021 · Filed October 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 407,916 |
Reported balance
After 2021-10-13 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2021-10-13 · Conversion · Acquired 407,916 · Balance 407,916 F1: The Series A Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. |
| Common StockSEC Table I · non-derivative | Direct | 510,971 |
Reported balance
After 2021-10-13 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2021-10-13 · Conversion · Acquired 103,055 · Balance 510,971 F2: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. |
| Common StockSEC Table I · non-derivative | Direct | 783,727 |
Reported balance
After 2021-10-13 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2021-10-13 · Conversion · Acquired 272,756 · Balance 783,727 F3: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. |
| Common StockSEC Table I · non-derivative | Direct | 2,047,302 |
Reported balance
After 2021-10-13 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2021-10-13 · Conversion · Acquired 1,263,575 · Balance 2,047,302 F4: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. |
| Common StockSEC Table I · non-derivative | Direct | 2,182,981 |
Reported balance
After 2021-10-13 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2021-10-13 · Conversion · Acquired 135,679 · Balance 2,182,981 F5: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. |
| Common StockSEC Table I · non-derivative | Direct | 2,210,452 |
Reported balance
After 2021-10-13 transaction · row 6
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 6 · 2021-10-13 · Other · Acquired 27,471 · Balance 2,210,452 |
| Common StockSEC Table I · non-derivative | Direct | 2,210,377 |
Reported balance
After 2021-10-13 transaction · row 7
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 7 · 2021-10-13 · Sale · Disposed 74.05 · Balance 2,210,377 F6: On October 13, 2021, the reporting person exercised a warrant to purchase 27,471 shares of CGTX common stock for $0.032 per share. The reporting person paid the exercise price on a cashless basis, resulting in CGTX's withholding of 74.05 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 27,396 shares. The issuer paid cash to the reporting person in lieu of any fractional share amounts. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-10-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-10-13 · Conversion · Disposed 1,319,408 · Balance 0 F1: The Series A Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-10-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-10-13 · Conversion · Disposed 333,333 · Balance 0 F2: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-10-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-10-13 · Conversion · Disposed 882,233 · Balance 0 F3: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-10-13 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-10-13 · Conversion · Disposed 4,087,046 · Balance 0 F4: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. |
| Series B-1 Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-10-13 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-10-13 · Conversion · Disposed 438,854 · Balance 0 F5: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2023-03-15 | Direct | 0 |
Reported balance
After 2021-10-13 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-10-13 · Other · Disposed 27,471 · Balance 0 F7: The warrant expires on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the issuer's IPO or (v) upon repayment of a promissory note issued in connection with the warrant. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
F2: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
F3: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
F4: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
F5: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
F6: On October 13, 2021, the reporting person exercised a warrant to purchase 27,471 shares of CGTX common stock for $0.032 per share. The reporting person paid the exercise price on a cashless basis, resulting in CGTX's withholding of 74.05 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 27,396 shares. The issuer paid cash to the reporting person in lieu of any fractional share amounts.
F7: The warrant expires on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the issuer's IPO or (v) upon repayment of a promissory note issued in connection with the warrant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | OtherWarrant (right to buy) · Derivative | 27,471 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · derivative · entry 13 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,471 shares Expires 2023-03-15 F7 · derivative.exercise_date: The warrant expires on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the issuer's IPO or (v) upon repayment of a promissory note issued in connection with the warrant. F7 · derivative.expiration_date: The warrant expires on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the issuer's IPO or (v) upon repayment of a promissory note issued in connection with the warrant. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries B-1 Convertible Preferred Stock · Derivative | 438,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · derivative · entry 12 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 135,679 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F5 · derivative.exercise_date: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F5 · derivative.expiration_date: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries B Convertible Preferred Stock · Derivative | 4,087,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · derivative · entry 11 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,263,575 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F4 · derivative.exercise_date: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F4 · derivative.expiration_date: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 882,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · derivative · entry 10 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 272,756 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F3 · derivative.exercise_date: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F3 · derivative.expiration_date: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 333,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · derivative · entry 9 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,055 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F2 · derivative.exercise_date: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F2 · derivative.expiration_date: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionSeries A Convertible Preferred Stock · Derivative | 1,319,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · derivative · entry 8 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 407,916 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F1 · derivative.exercise_date: The Series A Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. F1 · derivative.expiration_date: The Series A Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | SaleCommon Stock | 74.05 | $12.00 | $888.60 |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · nonDerivative · entry 7 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,210,377 F6 · kind: On October 13, 2021, the reporting person exercised a warrant to purchase 27,471 shares of CGTX common stock for $0.032 per share. The reporting person paid the exercise price on a cashless basis, resulting in CGTX's withholding of 74.05 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 27,396 shares. The issuer paid cash to the reporting person in lieu of any fractional share amounts. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | OtherCommon Stock | 27,471 | $0.03 | $879.07 |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · nonDerivative · entry 6 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,210,452 Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 135,679 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · nonDerivative · entry 5 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,182,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 1,263,575 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · nonDerivative · entry 4 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,047,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series B Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 272,756 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · nonDerivative · entry 3 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 783,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series A-2 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 103,055 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · nonDerivative · entry 2 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 21:51 UTC | COGNITION THERAPEUTICS INC CGTX · Entity 6792 | ConversionCommon Stock | 407,916 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-126903 · tm2130061-8_4seq1.xml · nonDerivative · entry 1 Ogden CAP Associates, LLC · CIK 0001885867 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.